Ipamorelin
A selective growth hormone secretagogue. Ipamorelin stimulates GH release with high selectivity, making it a cornerstone compound for growth hormone research.
Compound Profile
Pharmaceutical Data Sheet
Mechanism of Action
How Ipamorelin Works
Ipamorelin is a synthetic pentapeptide GHRP that acts as a selective agonist at the ghrelin receptor (GHS-R1a) in the pituitary, stimulating GH release with no clinically significant effect on cortisol, prolactin, or ACTH. This selectivity makes it the cleanest GH secretagogue in the peptide research toolkit.
- Selective agonism at pituitary GHS-R1a
- Triggers GH pulse without cortisol elevation
- No prolactin or ACTH co-stimulation
- Preserves physiological GH pulsatility
- GH release elevates hepatic IGF-1 production
- IGF-1 drives protein synthesis in muscle and bone
- Promotes lipolysis via GH/IGF-1 axis
- Synergistic with GHRH analogs (CJC-1295)
- Partially overcomes somatostatin inhibition
- Enables GH pulse during somatostatin-dominant phases
- Less desensitization than GHRP-2/GHRP-6
- Maintains pulsatile GH pattern with repeated dosing
Ipamorelin binds GHS-R1a, a Gq-coupled receptor on somatotrophs. Gq activation triggers phospholipase C (PLC), generating IP3 and DAG. IP3 releases intracellular calcium, which triggers exocytosis of growth hormone granules. Crucially, this pathway does not cross-activate CRH/ACTH for cortisol or TRH/TSH pathways, unlike GHRP-2 or GHRP-6.
Raun K et al., Eur J Endocrinol (1998): Ipamorelin — highly selective GH secretagogue.
Preclinical Findings
Research Models
Clinical Data
GH Pulse Augmentation Without Cortisol Side Effects
Clinical data demonstrates ipamorelin produces dose-dependent GH pulses with peak elevations 5–10× baseline at optimal doses (200–300mcg), with no significant changes in cortisol, prolactin, or ACTH — distinguishing it from earlier GHRPs.
Raun K et al., Eur J Endocrinol (1998): Selective GH release by ipamorelin in rats and humans.
Human pharmacodynamic study
Research Outcomes
Key Research Success Metrics
Safety Profile
Research Safety Notes
- No cortisol or prolactin elevation — key safety advantage over earlier GHRPs
- Well-tolerated across subcutaneous dosing routes in human studies
- Water retention possible at high doses due to GH effects on aldosterone
- No tachyphylaxis with standard dosing intervals in preclinical studies
- No receptor downregulation observed at studied doses
For research use only. GH-modulating compounds may have effects on glucose metabolism and other hormonal systems. Longitudinal human safety data is limited.
About Ipamorelin
A selective growth hormone secretagogue. Ipamorelin stimulates GH release with high selectivity, making it a cornerstone compound for growth hormone research.
All EVO Labs Research compounds are manufactured to research-grade standards and independently tested by Janoshik Analytical (Prague, est. 2013). The Certificate of Analysis for this compound includes full HPLC chromatography data, mass spectrometry confirmation, net purity percentage, and net content verification.
Research Use Only
This product is strictly for in vitro research and laboratory use only. Not for human or veterinary consumption. By purchasing, you confirm use in a controlled research setting.
